Aarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026
ArriVent BioPharma, Inc. (AVBP)
Company Research
Source: Business Wire
HAYWARD, Calif.--(BUSINESS WIRE)--Aarvik Therapeutics, an innovative, ADC-focused biotechnology company dedicated to engineering precision medicines for cancer therapy, is pleased to announce that it will present two posters and a minisymposium talk at the AACR Annual Meeting 2026. These presentations display the breadth of Aarvik’s capabilities in the ADC space. The AACR Annual Meeting will take place from April 17-22, 2026, in San Diego, California.Aarvik, along with collaborator ArriVent BioPharma, Inc. (Nasdaq: AVBP), will present a poster titled “AV-P138-ADC (ARR-002), a novel MUC16/NaPi2b dual-target tetravalent ADC, for the treatment of ovarian and endometrial cancers” (Poster Number 2660). AV-P138-ADC, also known as ARR-002, was discovered by Aarvik as part of a research collaboration with ArriVent, who subsequently exclusively licensed the molecule and plans global development. AV-P138-ADC (ARR-002) is a novel, site-specifically-conjugated, dual-target tetravalent ADC tha
Show less
Read more
Impact Snapshot
Event Time:
AVBP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVBP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVBP alerts
High impacting ArriVent BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics
AVBP
News
- ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Aarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026 [Yahoo! Finance]Yahoo! Finance
- ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual MeetingGlobeNewswire
- ArriVent BioPharma (AVBP) was upgraded by BTIG Research to "strong-buy".MarketBeat
- ArriVent BioPharma (AVBP) had its "buy" rating reaffirmed by BTIG Research. They now have a $42.00 price target on the stock.MarketBeat
AVBP
Earnings
- 3/5/26 - Miss
AVBP
Sec Filings
- 3/17/26 - Form 8-K
- 3/5/26 - Form S-8
- 3/5/26 - Form 10-K
- AVBP's page on the SEC website